About Us
Our Company
Leadership
Contact
Medical Education Grants
Product
Candidates
Pipeline VP-102
Pipeline VP-103
Pipeline LTX-315
R & D
Key Publications
Investors &
Media
Investor Overview
Press Releases
Analyst Coverage
Presentations & Events
Stock Information
SEC Filings
Corporate Governance
Investor FAQs
Investor Connection
Careers
Menu
About Us
Our Company
Leadership
Contact
Medical Education Grants
Product
Candidates
Pipeline VP-102
Pipeline VP-103
Pipeline LTX-315
R & D
Key Publications
Investors &
Media
Investor Overview
Press Releases
Analyst Coverage
Presentations & Events
Stock Information
SEC Filings
Corporate Governance
Investor FAQs
Investor Connection
Careers
Press Releases
Press Releases
Year
2018
2019
2020
2021
2022
Submit
June 28, 2022
Verrica Pharmaceuticals Holds Type A Meeting with FDA for VP-102 for Molluscum Contagiosum
May 24, 2022
Verrica Receives Complete Response Letter from the FDA for its NDA for VP-102 as a Direct Result of Deficiencies at General Reinspection of Sterling Pharmaceuticals Services, LLC
May 9, 2022
Verrica Pharmaceuticals Reports First Quarter 2022 Financial Results
April 7, 2022
Verrica Pharmaceuticals Announces Participation in the 21st Annual Needham Virtual Healthcare Conference
April 5, 2022
Verrica Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of LTX-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma
1
2
next >
